Compass Therapeutics provides pipeline update; cash at $127M, tovecimig data Q1 2025

Compass Therapeutics, Inc.

Estimated $127M cash at YE 2024; cash runway expected into Q1 2027.
Top-line Phase 2/3 data for tovecimig (CTX-009) in BTC expected end of Q1 2025.
New drug candidate CTX-10726 (PD-1 x VEGF-A bispecific) advancing; IND submission targeted by YE 2025.
Third dosing cohort fully enrolled for CTX-8371 Phase 1; preliminary data H2 2025.
Two Phase 2 biomarker trials planned for mid-2025: tovecimig in DLL4+ CRC and CTX-471 in NCAM/CD56+ tumors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.